ArticleJournal of the American Society of Nephrology : JASN2017
Clinical and Genetic Spectrum of Bartter Syndrome Type 3.
Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 118 citations in OpenAlex.
- Adjunctive acetazolamide therapy for the treatment of Bartter syndrome.International urology and nephrology · 2020Trial
- Copeptin in the diagnosis and management of renal tubular disorders.Pediatric nephrology (Berlin, Germany) · 2026Review
- Gitelman Syndrome in a Child Presenting With Polyuria and Polydipsia: Diagnostic Challenges in a Resource-Limited Setting.Case reports in nephrology · 2026Article
- An Atypical Presentation of Bartter Syndrome Type 3 With Hypocalciuria and Opisthotonus Posture in a Preterm Infant.Clinical case reports · 2025Article
- Fetal umbilical vein thrombosis associated with fetal bartter syndrome: an unusual case report and literature review.BMC pregnancy and childbirth · 2025Review
- Genetic background of neonatal hypokalemia.Pediatric nephrology (Berlin, Germany) · 2025Review
- Integrated transcriptomic and single-cell RNA-seq analysis identifies CLCNKB, KLK1 and PLEKHA4 as key gene of AKI-to-CKD progression.Frontiers in immunology · 2025Article
- Article
- Clinical, genetic characteristics and outcome of four Chinese patients with Bartter syndrome type 3: Further insight into a genotype-phenotype correlation.Molecular genetics and metabolism reports · 2024Article
- ClC-K Kidney Chloride Channels: From Structure to Pathology.Handbook of experimental pharmacology · 2024Article
- Long-read sequencing identifies a common transposition haplotype predisposing for CLCNKB deletions.Genome medicine · 2023Article
- Genotypic variability in patients with clinical diagnosis of Bartter syndrome type 3.Scientific reports · 2023Article
- Genetic diagnosis and treatment of hereditary renal tubular disease with hypokalemia and alkalosis.Journal of nephrology · 2023Review
- Bartter syndrome type III with glomerular dysplasia and chronic kidney disease: A case report.Frontiers in pediatrics · 2023Review
- Bartter Syndrome: Perspectives of a Pediatric Nephrologist.Electrolyte & blood pressure : E & BP · 2022Review
- Model organisms for functional validation in genetic renal disease.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2022Article
- Genetic diagnosis of Bartter syndrome in Iranian patients and detection of a novel homozygousClinical case reports · 2022Article
- Potassium and the kidney: a reciprocal relationship with clinical relevance.Pediatric nephrology (Berlin, Germany) · 2022Review
- The Bartter-Gitelman Spectrum: 50-Year Follow-up With Revision of Diagnosis After Whole-Genome Sequencing.Journal of the Endocrine Society · 2022Article
- A novel mutation of KCNJ1 identified in an affected child with nephrolithiasis.BMC nephrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bartter syndrome type 3 is a clinically heterogeneous hereditary salt-losing tubulopathy caused by mutations of the chloride voltage-gated channel Kb gene (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.